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Mitochondrial dysfunctions mark a critical step in many central nervous system (CNS) 28 
pathologies, including multiple sclerosis (MS). Such dysfunctions lead to depolarization of 29 
mitochondrial membranes and imbalanced redox homeostasis. In this context, reactive oxygen 30 
species (ROS) are potentially deleterious but can also act as an important signaling step for 31 
cellular maintenance. The transcription factor nuclear erythroid2 like 2 (Nrf2), the key regulator 32 
in the cellular oxidative stress-response, induces a battery of genes involved in repair and 33 
regeneration. Here, we investigated the relevance of Nrf2-signaling for the prevention of 34 
cellular damage caused by dysfunctional mitochondria. We employed sodium azide (SA) as 35 
mitochondrial inhibitor on oligodendroglial OliNeu cells in vitro, and the cuprizone model with 36 
wild type and GFAP-Cre+:Keap1loxP/loxP mice to induce mitochondrial defects. The importance 37 
of Nrf2 for cellular functions and survival after SA-treatment was elucidated by in vitro 38 
knockdown experiments with shRNA directed against Nrf2 and its inhibitor Keap1 as well as 39 
by methysticin treatment. Metabolic activity, cytotoxicity, and depolarization of the 40 
mitochondrial membrane were analyzed after SA-treatment. The expression of Nrf2 target 41 
genes as well as endoplasmic reticulum stress response genes was additionally measured by 42 
real-time PCR (in vitro) and PCR gene arrays (in vivo). Treatment of OliNeu cells with SA 43 
resulted in significant depolarization of the mitochondrial membrane, decreased metabolic 44 
activity and increased cytotoxicity. This was partly counteracted in Nrf2-hyperactivated cells 45 
and intensified in Nrf2-knockdown cells. Our studies demonstrate a key of Nrf2 in maintaining 46 
cellular functions and survival in the context of mitochondrial dysfunction.  47 
 48 




Although the pathomechanisms of MS are not fully understood there is ample evidence that 53 
mitochondrial dysfunctions play a crucial role in the neurodegenerative and neuroinflammatory 54 
aspects of this disease (Campbell et al. 2014; Witte et al. 2014). Underlying processes that 55 
initially cause mitochondrial dysfunctions have not been completely investigated. However, 56 
distinct mutations in mitochondrial (mt) DNA  are known to increase the risk of MS 57 
development, and the majority of these mutations concern subunits of the mitochondrial 58 
electron transport chain (Patergnani et al. 2017). Also of note, mtDNA is prone to mutations with 59 
a mutation rate that is about 10-fold higher than in chromosomal DNA (Linnane et al. 1989). 60 
This finding might be explained by the close spatial relation of mtDNA with the inner 61 
mitochondrial membrane, where endogenous ROS are generated. In addition, 62 




associated with mitochondrial dysfunctions, thereby contributing to neuronal injury and 64 
degeneration (Carvalho 2013).  65 
Mitochondria are primarily involved in adenosine triphosphate (ATP) synthesis, Ca2+ 66 
regulation, and the production of endogenous ROS. Consequently, mitochondrial damage in 67 
the course of MS may lead to both inadequate energy production as well as oxidative stress. 68 
Elevated ROS-levels are harmful to both neurons and glia, however, oligodendrocytes, the 69 
myelin producing cells of the CNS, are especially vulnerable to both oxidative stress and 70 
mitochondrial dysfunctions (Juurlink et al. 1998; Lan et al. 2018). This vulnerability can be 71 
explained by the unique oligodendrocyte physiology. A high lipid synthesis rate of 72 
oligodendrocytes leads to elevated auto-oxidation of cholesterol to 7-keto- (7KC), 7a-hydroxy- 73 
and 7b-hydroxy-cholesterol. This lipid molecule is involved in demyelination by inducing 74 
oligodendrocyte cell death via a disruption of mitochondrial membrane structures, the 75 
activation of caspase-3-dependent apoptosis and the induction of oxidative stress (Leoni et al. 76 
2016). Furthermore, oligodendrocytes display a very high metabolic rate, store large amounts 77 
of intracellular iron and possess only low concentrations of the anti-oxidative enzyme 78 
glutathione (Bradl and Lassmann 2010; Lan et al. 2018), all of them characteristically 79 
contributing to oligodendroglial vulnerability to oxidative damage. Thus, mitochondria-related 80 
mechanisms such as decreased activity of the mitochondrial electron transport chain by 81 
damage or mutation, concomitant impairment of mitochondrial energy metabolism and 82 
inefficient removal of ROS might contribute to oligodendrocyte loss during MS lesion formation 83 
and disease progression (Licht-Mayer et al. 2015).  84 
In general, all eukaryotic cells possess highly effective mechanisms to counteract and prevent 85 
oxidative challenges. The main regulation of these responses is orchestrated by the nuclear 86 
factor (erythroid-derived 2)-like 2/antioxidant response element system (Nrf2/ARE system) that 87 
recently has come into the focus of MS research (Lu et al. 2016). Upon induction, Nrf2 is 88 
stabilized in its “closed” state bound to two molecules of its inhibitor Kelch ECH associating 89 
protein 1 (Keap1). As a consequence, newly synthesized Nrf2 is not further scavenged by 90 
Keap1 and can thereby bind to the ARE sequence within the promoter region of its target 91 
genes (Baird et al. 2013). With respect to MS, the targeting of Nrf2/ARE signaling by dimethyl 92 
fumarate promotes mitochondrial biogenesis, restores gene expression and function (Hayashi 93 
et al. 2017), and patients treated with dimethyl fumarate benefit from a significant reduction in 94 
relapse rate, disability progression and brain lesions (Al-Sawaf et al. 2015; Bomprezzi 2015). 95 
In oligodendrocytes, the activation of the Nrf2/ARE system triggers the expression of 96 
endoplasmic reticulum-stress related genes such as Ddit3 and ATF3 (Teske et al. 2018).  97 
In this study, we investigated a particular aspect of oligodendrocyte physiology related to MS 98 
pathophysiology, i.e. the potential of this glial cell type to counteract mitochondrial challenges 99 




Materials and Methods 101 
 102 
Cell culture 103 
The murine oligodendroglial cell line OliNeu was cultured in SATO medium containing 2% fetal 104 
bovine serum (FBS). SATO is composed of DMEM (Gibco Life Technologies, #41966-029) 105 
with 1% bovine serum albumin (BSA, Carl ROTH, #CP84.2), 1% N2 Supplement (Gibco Life 106 
Technologies, #17502-048), 1% Penicillin/Streptomycin 100x10.000 U/ml (Gibco Life 107 
Technologies, #15140-122), 0.1% N-Acetylcystein (Sigma-Aldrich, #9165), 0.002% Biotin 108 
(Sigma-Aldrich, #B4639). 109 
Cells were treated with concentrations in a range from 1 mM to 100 mM of sodium azide (SA) 110 
for up to 24 h. Methysticin pre-treatments were done with 50 µM for 6 h prior to SA stimulation. 111 
For qRT-PCR experiments, OliNeu cells were seeded on poly-D-lysine (PDL, Sigma #P6407) 112 
coated 6-well plates at a density of 3 x 105 cells/well and exposed to starvation conditions 113 
(SATO containing 0.5% FBS) for 48 h. After the treatment regimen, the cells were washed 114 
once with 1x PBS and lysed in PeqGold (peqlab, #30-1010) for RNA isolation and subsequent 115 
qRT-PCR (see below). Methysticin treatment (LKT Laboratories, #M1679) served as a positive 116 
control for Nrf2-Induction. 117 
Lactate dehydrogenase release (LDH) measurement was performed using CytoTox 96 Non-118 
Radioactive Cytotoxicity Assay (LDH, Promega, #G1780). Metabolic activity was determined 119 
via CellTiter-Blue Cell Viability Assay (CTB, Promega, #G8080). Both assays were used 120 
according to the manufacturer´s instruction. For experiments, cells were plated in 96-well 121 
plates at a density of 1.5 x 104 cells/well and grown in phenol red-free SATO. Methysticin pre-122 
treatments were done with 50 µM for 6 h prior to SA treatments. After this, the absorbance 123 
(LDH) and the fluorescence (CTB) of the supernatant were measured using the Inf inite M200 124 
microplate reader (Tecan, Switzerland). CytoTox 96 results were normalized to lysed cells 125 
(100% dead cells) and in case of shRNA experiments additionally related to  shNT group. CTB 126 
data was normalized to untreated control cells (=100% viability).  127 
Animal experiments 128 
The relevance of Nrf2 activity during mitochondrial inhibition in vivo was investigated by 129 
applying the cuprizone model to wild type (WT) as well as astrocyte-specific Keap1-KO mice 130 
(GFAP-Cre+::Keap1loxP/loxP). Therefore, mice were either fed with normal chow (n = 4) or with 131 
chow containing cuprizone for 1 week (n = 3). The mice were euthanised by cervical 132 
dislocation,  and brain tissue was isolated for gene array analysis (see below). The 133 
experiments were conducted in accordance with the Directive 2010/63/EU of the European 134 





Gene silencing 137 
Nrf2 and Keap1 gene expression was silenced in OliNeu cells by lentiviral shRNA delivery (see 138 
Fig. S1 in the supplemental material). For that purpose, we used commercially available 139 
pLKO.1 vectors encoding shRNA sequences for either Nrf2 (TRC clone ID: 140 
TRCN0000054659) or Keap1 (TRC clone ID: TRCN0000099447). These vectors are part of 141 
the MISSION® shRNA contingent distributed by Sigma Aldrich (Munich, Germany). For virus 142 
production HEK293T cells (ATCC®CRL-11268™) were co-transfected with the shRNA 143 
expression vector pLKO.1, the VSV-G envelope expressing pMD2.G construct (addgene 144 
#12259) and the 2nd generation lentiviral packaging plasmid psPAX2 (addgene #12260). 145 
Transfection was conducted by using jetPEI® (Polypus Transfection™, #101) transfection 146 
reagent according to the manufacturer´s instruction (Teske et al. 2018). For transduction, cells 147 
were re-plated on poly-D-lysin coated culture dishes in SATO supplemented with 2% FBS. The 148 
cells were exposed to the virus containing supernatant for 16 h, afterwards they were washed 149 
with PBS and cell culture medium was replaced. After 72 h, puromycin (Carl ROTH, #0240.1) 150 
was constantly supplemented to the medium at a concentration of 2 µg/mL to assure sufficient 151 
selection of transduced cells. After positive selection, the gene expression levels of Nrf2 and 152 
Keap1 were measured by qRT-PCR to determine knockdown efficiency. Control cells were 153 
transduced with a pLKO.1 construct expressing a shRNA without any target in mammals 154 
(pLKO.1-shNonTarget; #SHC216) to avoid data misinterpretation based on transduction side 155 
effects (Teske et al. 2018). 156 
Measurement of mitochondrial membrane potential levels 157 
Mitochondrial membrane potential was quantified using the Muse™ MitoPotential Kit (Merck, 158 
Germany, #MCH100110) together with the benchtop flow cytometry device Muse Cell Analyzer 159 
(Merck, Germany). To this end, cells were seeded onto 9.6 cm2 (~5x105 cells) plastic culture 160 
dishes pre-coated with 10 µg/mL poly-D-lysine in modified SATO-medium. Modified SATO is 161 
composed of DMEM with 1% N2 supplement (Gibco Life Technologies, #17502-048), 0.1% 162 
Tri-Iodo-thyronine (Sigma-Aldrich, #T6397), 0.016% L-thyroxin (Sigma-Aldrich, #T1775) and 163 
0.05 % Gentamicin (Gibco Life Technologies, #15710049). After 47 h, cells were exposed to 164 
100 mM SA for another 60 min and then harvested using TrypLE™ Express enzyme solution 165 
(Gibco Life Technologies, #12604039). Thereafter, cells were stained and flow cytometry 166 
analyses were performed according to the manufacturer´s instruction. To avoid any bias, 167 
gating of the different cell populations was performed in a blinded manner (NT). Experiments 168 
were performed with six biological and one technical replicate. 169 
Gene expression  170 
Gene expression levels were measured by real-time reverse transcription-PCR (qRT-PCR). 171 




isolated according to the manufacturer’s protocol. The measurement of the RNA concentration 173 
und purity was performed by the NanoDrop 1000 (Thermo Fisher Scientific, USA). For reverse 174 
transcription the MMLV reverse transcriptase kit (Invitrogen, #28025013) was used. The qRT-175 
PCR was performed by SYBR Green SensiMixTM (Bioline, #QT615-05) and carried out on the 176 
MyIQ RT-PCR detection system (Biorad, Germany) applying a standardized protocol as 177 
published previously (Clarner et al. 2011). Relative quantification was performed using the 178 
ΔCq method with hypoxanthine guanine phoshoribosyl transferase (Hprt) as a reference gene. 179 
Primer sequences were as follows: 180 
Hprt1 (F: TCAGTCAACGGGGGACATAAA, R: GGGGCTGTACTGCTTAACCAG), 181 
Ddit3 (F: GCATGAAGGAGAAGGAGCAG, R: CTTCCGGAGAGACAGACAGG), 182 
Atf3 (F: TTTGCTAACCTGACACCCTTTG, R: ATGGCGAATCTCAGCTCTTCC), 183 
Nrf2 (F: CCCAGCAGGACATGGATTTGA, R: AGCTCATAGTCCTTCTGTCGC), 184 
Keap1 (F: GGCAGGACCAGTTGAACAGT, R: CATAGCCTCCGAGGACGTAG), 185 
Nqo1 (F: AGAGAGTGCTCGTAGCAGGAT, R: CTACCCCCAGTGGTGATAGAAA). 186 
 187 
In vivo gene array 188 
RNA from the corpus callosum of cuprizone- and normal chow-fed WT as well as 189 
GFAP-Cre+::Keap1loxP/loxP mice were isolated using the RNeasy Lipid Tissue Mini Kit (Cat.#: 190 
74804, Qiagen) following the manufacturer’s instructions. RNA was quantified as above and 191 
subsequently reverse-transcribed using the RT2 First Strand Kit (Cat.#: 330404, Qiagen) as 192 
recommended. Obtained cDNA samples were used for mouse Unfolded Protein Response 193 
RT2 Profiler PCR arrays (Cat.#: PAMM-089, Qiagen) comprising 84 key genes involved in ER 194 
stress response. 195 
 196 
Statistics 197 
Statistical analyses were performed using Prism 5 (GraphPad Software Inc., San Diego, CA, 198 
USA). All data are given as arithmetic means + SEM. A p value of < 0.05 was considered to 199 
be statistically significant. Applied statistical tests including the number of individual 200 
independent experiments (n) are given in the respective figure legends. No outliers were 201 
excluded from the analyses. 202 
Results 203 
Inhibition of complex IV by SA induces mitochondrial dysfunction in vitro 204 
Wild type OliNeu cells were stimulated with different concentrations of SA for 24 h to 205 
specifically inhibit the mitochondrial complex IV and to investigate the impact on mitochondrial 206 
membrane polarization. Methysticin pre-treatment was conducted to investigate whether  207 




of the stress-related genes Ddit3 and Atf3. SA treatment with 1 mM of SA neither affected 209 
metabolic activity nor cell viability (Fig. 1A and B, 2nd column) in OliNeu cells. Stimulation with 210 
10 mM of SA decreased metabolic activity by 18 % in comparison to untreated cells despite 211 
any signs of cytotoxicity (Fig. 1A and B, 3rd column). Increasing the SA concentration to 100 212 
mM resulted in significant reduction of metabolic activity by 82 % and increased cytotoxicity 213 
respectively (Fig. 1A and B, 4th column). Moreover, this treatment regimen significantly 214 
increased the percentage of cells displaying mitochondrial membrane depolarization (Fig. 1C). 215 
Methysticin pre-treatment did not counteract the early cytotoxic effects of SA as shown in Fig. 216 
1D (6h time point). However, it significantly reduced cytotoxicity when OliNeu cells were 217 
stimulated for 24 h (Fig. 1D, 24h time point). The qRT-PCR experiments revealed that Ddit3 218 
gene expression was significantly increased after methysticin and methysticin + SA but not 219 
after SA single treatment (Fig. 1E). Both methysticin as well as SA treatment induced the gene 220 
expression of Atf3 significantly. Notably, Atf3 expression was even more increased after co-221 
treatment with both substances (Fig. 1F).  222 
ER stress responses in mice with Nrf2-hyperactivation  223 
The induction of ER-stress related factors such as Ddit3 was further investigated in vivo using 224 
mice with an GFAP-specific Keap1-deletion (see Materials and Methods) applying Mouse 225 
Unfolded Protein Response RT2 Profiler PCR arrays. Results of this study are summarized in 226 
supplementary data 1. Note that Ddit3 was induced in both WT and Keap1-deficient animals 227 
in response to cuprizone. In total, 13 ER-stress related genes were altered  (7 up- and 6 down-228 
regulated) in response to cuprizone in WT mice. In Keap1-deficient animals 21 genes were 229 
regulated (19 up- and 2 down-regulated). However, none of these cuprizone-regulated genes 230 
showed a significant difference in between WT and Keap1-KO, indicating comparable 231 
response to cuprizone for both genotypes.  232 
Confirmation of shRNA–mediated knockdown of Keap1 and Nrf2 in OliNeu cells 233 
After transduction of OliNeu cells with lentiviral particles containing shRNA constructs against 234 
either Keap1 (shKeap1) or Nrf2 (shNrf2), knockdown effects and efficiency were analyzed. 235 
Control cells were transduced with a construct encoding for a non-target shRNA sequence 236 
(shNT). Selected cultures were viable and displayed comparable densities under normal 237 
growth conditions. Representative images of each are depicted in Fig. 2A. To test for shRNA-238 
mediated knockdown efficiency, we conducted qRT-PCR experiments. For this purpose, the 239 
gene expression of Keap1, Nrf2 as well as the Nrf2 target gene NAD(P)H quinone 240 
dehydrogenase 1 (Nqo1) was analyzed. Nqo1 has been chosen as readout because to our 241 
knowledge, Nrf2 is the only described regulator of its gene expression. These experiments 242 
revealed knockdown efficiencies of 72 % for Keap1 (Fig. 2B) and 67 % for Nrf2 (Fig. 2C). This 243 
was further confirmed by the analysis of Nqo1 expression as seen in Fig. 2D. Methysticin 244 




used as positive control. Besides from significant differences of Nqo1 expression in between 246 
unstimulated cultures, methysticin effectively induced the expression of Nqo1 in both shNT 247 
and shKeap1 cells. In contrast, Nrf2-deficient cells did not display a significant induction of 248 
Nqo1. 249 
Nrf2 prevents SA-mediated cell death and restores mitochondrial functions  250 
To analyze the effects of Nrf2-expression on SA-induced mitochondrial dysfunctions, cells 251 
were treated with 100 mM SA for 2, 6 and 24 h and the metabolic activity, LDH-release and 252 
mitochondrial depolarization were measured. Results are summarized in Fig. 3. As shown in 253 
A, the metabolic activity decreased in a time-dependent manner in all cell lines. Differences 254 
between the shNrf2 and the other cell lines were only found after 2 h and 6 h SA-treatment. 255 
SA-treatment for 2 h already decreased the metabolic activity of shNT cells to 71 % of 256 
untreated control cells. The Keap1 knockdown tended to be beneficial in this context (79 %, 257 
without statistical significance). In contrast, Nrf2 knockdown clearly decreased metabolic 258 
activity after 2 h SA-treatment (44 %) compared to shNT as well as shKeap1 cells (Fig. 3A, 2 259 
h panel). The decrease of metabolic activity was further intensified after 6 h SA-treatment. 260 
Although the Keap1 knockdown did not display any benefit, Nrf2 silencing resulted in 261 
worsening of SA-toxicity (Fig. 3A, 6 h panel; 39 % vs. 43 % vs. 13 %). Cell viability assays (Fig. 262 
3B) highlighted the necessity of Nrf2-signalling for cell survival after SA-treatment. Similar to 263 
the observed SA effects on metabolic activity, LDH-release showed a significant genotype 264 
effect (*** p < 0.001) which was highest in the shNrf2-group at all investigated time points. Of 265 
note, Nrf2 hyper-activation due to Keap1 knockdown only slightly improved cell viability after 266 
SA-treatment, since LDH-release was almost comparable to treated shNT cells independent 267 
from the stimulation time point. Since the observed protective effects of Nrf2-signalling might 268 
be due to restored mitochondrial functions, amount of depolarized cells after SA stimulation 269 
was investigated in the next step. As shown in Fig. 3C, Keap1 knockdown significantly reduced 270 
the amount of depolarized cells after 1 h SA-stimulation compared to shNT cells. Additionally, 271 
the total amount of living cells was increased (Fig. 3D). The opposite effect was observed in 272 
SA-stimulated Nrf2 knockdown cells (Fig. 3E and F). 273 
Discussion 274 
Mitochondria are regulators of the intracellular redox as well as Ca2+ homeostasis. 275 
Furthermore, they are a relevant source of ROS which are crucial for the control of a variety of 276 
intracellular signaling pathways (Guzman-Villanueva and Weissig 2017) such as Nrf2/ARE. 277 
Imbalances of mitochondrial homeostasis have been described to be critically involved in 278 
pathophysiological different diseases such as Morbus Alzheimer (Fragoulis et al. 2017), 279 




Amyotrophic lateral sclerosis (ALS) (Faes and Callewaert 2011) and MS (Campbell and Mahad 281 
2018; Campbell et al. 2014). 282 
Mitochondrial dysfunctions are characterized by decreased respiratory enzyme activity and 283 
ATP production and contribute to the age-related risk to develop neurodegenerative diseases 284 
(Lin and Beal 2006). Lower respiration rates lead to lower intracellular ATP concentrations which 285 
directly affect and decrease the mitochondrial potential. This can initiate mitochondrial swelling 286 
and ultimately trigger apoptotic cascades (Irvin et al. 2015; Safiulina et al. 2006). The impact of 287 
lower ATP concentrations on oxidative imbalances is bi-directional and further impairs 288 
mitochondrial function (Cassina et al. 2008; Cozzolino and Carri 2012). l. The mitochondrial 289 
respiratory chain consists of five complexes (I–V). Most of the oxygen (90 %) is consumed by 290 
complex IV, the rate limiting step of electron transport chain. Complex IV defects in acute MS 291 
lesions impair cellular functions of oligodendrocytes, astrocytes, and axons (Ziabreva et al. 292 
2010). Oligodendrocytes are known to be particularly susceptible to pathologic events such as 293 
hypoxia, excitotoxicity, reactive oxygen, and nitrogen species, and the subsequent loss of 294 
oligodendrocytes has been functionally linked to mitochondrial dysfunctions (Ziabreva et al. 295 
2010). The use of SA as an inhibitor of mitochondrial complex IV (Bennett et al. 1996) is a well-296 
characterized model to induce “chemical hypoxia” (Ziabreva et al. 2010) and membrane 297 
depolarization in oligodendrocytes (Teske et al. 2018). Since SA-treatment leads to both a 298 
decrease in cellular ATP levels (Harvey et al. 1999) and an increase in net ROS production (Gao 299 
et al. 2018), it can be considered as suitable model to investigate mitochondrial dysfunctions in 300 
vitro. Furthermore, SA has been described to induce mitochondrial swelling in neurons, 301 
thereby inhibiting axonal transport (Kaasik et al. 2007). 302 
Other processes by which mitochondrial dysfunctions are thought to contribute to the 303 
development of neurodegenerative diseases are the disturbance of the production and 304 
removal of endogenous ROS leading to a net ROS over-production and thereby to oxidative 305 
stress. This promotes then a vicious cycle in which ROS can further damage mitochondria, 306 
causing more free-radical generation and a loss of the antioxidant capacity (Lin and Beal 2006). 307 
With respect to multiple sclerosis, mitochondrial dysfunctions and oxidative stress are likely to 308 
critically contribute to lesion development and progression, and oxidative stress markers can 309 
be found in the blood plasma, saliva, liquor and brain tissue of MS patients (De Riccardis et al. 310 
2018; Karlik et al. 2015; Mao and Reddy 2010; Morel et al. 2017; Shu et al. 2017). Oxidized 311 
lipids (phospholipids), proteins and DNA have been demonstrated in astrocytes, macrophages, 312 
myelin proteins, damaged axons and in particular in oligodendrocytes (Cross et al. 1998; 313 
Haider et al. 2011; Liu et al. 2001; Qin et al. 2007; van Horssen et al. 2008). 314 
Nrf2 is the main regulator of cellular defense-mechanisms preventing oxidative damage 315 




presence of high levels of nuclear Nrf2 within damaged oligodendrocytes in MS lesions, 317 
indicating the relevance of the oligodendroglial Nrf2/ARE system during MS lesion formation 318 
(Licht-Mayer et al. 2015). In their study, the authors speculated that the pharmacological 319 
induction of Nrf2 by fumarate might cause additional cell stress in oligodendrocytes or neurons 320 
already exposed to severe oxidative injury (and thereby already displaying high endogenous 321 
Nrf2-activity).To further investigate this assumption in vitro, the cell lines described by Teske 322 
and colleagues (Teske et al. 2018) were utilized. These cells exhibit a stable and functional 323 
expression of shRNAs directed against both Nrf2 and its endogenous inhibitor Keap1. These 324 
novel cell lines are therefore useful tools to study the role of Nrf2 in the context of demyelinating 325 
diseases or oligodendrogliopathy (Draheim et al. 2016). 326 
We recently demonstrated that oxidative stress in oligodendrocytes activates an ER stress 327 
response in a Nrf2-dependent manner (Teske et al. 2018). In the current study, we show that 328 
the pharmacological activation of Nrf2 by methysticin leads to a similar inductive effect in vitro. 329 
Furthermore, we used the cuprizone animal model to induce oligodendrocyte specific stress 330 
and death by inhibiting mitochondria (Acs et al. 2013). As expected, such treatment induced 331 
ER stress related genes in wild type animals. In animals displaying astrocyte-specific 332 
hyperactivation of Nrf2, a higher induction of ER stress related genes was expected. However, 333 
the induction of these genes was comparable in between both genotypes. This might be 334 
explained by the fact that due to Nrf2-hyperactivation the cuprizone-induced damage and 335 
neuroinflammation is reduced (Draheim et al. 2016) and the activation of a potentially 336 
protective ER stress response is moderated or not required. 337 
Additionally, our results demonstrate the relevance of Nrf2-signaling for the maintenance of 338 
mitochondrial function in oligodendrocytes. While Nrf2-deficiency intensifies both cell death as 339 
well as membrane potential breakdown in an SA-mediated manner, both genetic, as well as 340 
the pharmacological hyper-activation of Nrf2 lead to a (partial) restoration of mitochondrial 341 
functions, improving cell survival. Therefore, Nrf2-activation in oligodendrocytes might 342 
represent a possible approach to counteract mitochondrial dysfunctions even under 343 
circumstances of prevalent oxidative damage. Further studies using oligodendrocyte-specific 344 
hyperactivation of Nrf2 may elucidate its potential to counteract mitochondrial dysfunctions in 345 
brain diseases that involve oligodendrocyte damage or loss. 346 
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Fig. 1: Inhibition of complex IV by SA induces cellular stress and mitochondrial 356 
dysfunction which are partly prevented by methysticin pre-treatment 357 
In (A) results from cell viability measurements of OliNeu cells treated with SA for 24 h are 358 
shown. SA decreases metabolic activity (A) and increases cytotoxicity (B) in a dose-dependent 359 
manner. (C) Mitochondrial membrane potential in OliNeu cells after 1 h SA (100 mM) exposure 360 
is shown. (D) LDH release after SA treatment for 6 and 24 h with or without methysticin pre-361 
treatment. Gene expression of (E) Ddit3 and (F) Atf3 after methysticin and SA treatment was 362 
analyzed by qRT-PCR. Comparison of control vs. SA-treated cultures was performed by 363 
students t-test (C, n=6) or 1way ANOVA followed by Bonferroni post hoc test (A, B, D & E n=4). 364 
Comparisons of multi-parametric data were achieved by 2way ANOVA followed by Bonferroni 365 
post-hoc test (D, n=6). Significant differences with respect to controls or as indicated by 366 




Fig. 2: shRNA–mediated knockdown of Keap1 and Nrf2 in OliNeu cells 368 
(A) Representative pictures of shRNA-transduced cells are shown. In (B & C) the relative 369 
Keap1 or Nrf2 mRNA expression of the respective shRNA clones is shown in comparison to 370 
non-target shRNA cells (shNT); n=9. Students t-test was performed to test for statistical 371 
significance. In (D), the transcription levels of the Nrf2-target gene Nqo1 is shown in the distinct 372 
cell lines. Methysticin treatment (50 µM) was used to induce Nrf2-dependent induction of Nqo1 373 
mRNA expression; n=4.  Note that basal Nqo1 expression was elevated in shKeap1 cells in 374 
comparison to shNT cells. Methysticin failed to induce Nqo1 expression in shNrf2 cells. 375 
Significant differences were calculated by 1way ANOVA followed by Bonferroni post-hoc test 376 




Fig. 3: Nrf2 prevents SA-mediated cell death and restores mitochondrial functions  378 
Metabolic activity (A) and cytotoxicity (B) of shKeap1, shNT and shNrf2 OliNeu cells after 2 h, 379 
6 h and 24 h SA treatment (n≥6) are shown. Note that Nrf2-deficient cells display reduced 380 
metabolic activity after 2 h and 6 h treatment (A). Furthermore, Nrf2-deficiency led to higher 381 
cell death (LDH-release) after 6 h SA exposure. Statistical significance was evaluated using 382 
2way ANOVA with subsequent Bonferroni post-hoc test in case of significant interaction 383 
(significant differences are indicated). Mitochondrial membrane potential measures in shNT, 384 
shNrf2 and shKeap1 OliNeu cells after 1 h SA (100 mM) exposure are shown in C-F. 385 
Comparison of differences between shNT and shKeap1 as well as shNT and shNrf2 cells (n=6) 386 
was done applying Students t-test. Significant differences with respect to control cultures are 387 
indicated as * p < 0.05, ** p < 0.01, *** p < 0.001. Viable cells with a breakdown of the 388 
mitochondrial membrane potential (C, E) and the sum of viable cells with or without a 389 
breakdown of the mitochondrial membrane potential (D, F) were separately compared. Note 390 
that the hyper-activation of Nrf2 by Keap1-knockdown protects cells from mitochondrial 391 




Supplementary Figure 393 
Fig. S1: The Nrf2/Keap1 axis and applied shRNA strategies for KD experiments 394 
(left side) Under steady-state conditions, Nrf2 is scavenged by its intracellular inhibitor Keap1. 395 
This interaction leads directly to 26S proteasome-mediated degradation of Nrf2. In the 396 
presence of Nrf2 activating stimuli, Keap1 dissociates from Nrf2 and enables its nuclear 397 
translocation. There, Nrf2 binds to the anti-oxidant response elements (ARE) within the 398 
promoter region of its target genes and thereby induces or enhances their gene expression. 399 
(right side) In our experiments, we applied shRNA against Keap1 to decrease Keap1 protein 400 
content and thereby boost the Nrf2 activation in OliNeu cells even under steady-state 401 
conditions. The use of shRNA directed against Nrf2 was chosen to decrease Nrf2 activity in 402 
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